Mn Services Vermogensbeheer B.V. Cuts Position in Bristol-Myers Squibb (NYSE:BMY)

Mn Services Vermogensbeheer B.V. decreased its position in shares of Bristol-Myers Squibb (NYSE:BMY) by 2.2% during the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 804,254 shares of the biopharmaceutical company’s stock after selling 18,400 shares during the period. Mn Services Vermogensbeheer B.V.’s holdings in Bristol-Myers Squibb were worth $33,401,000 at the end of the most recent reporting period.

Other hedge funds have also recently added to or reduced their stakes in the company. First Merchants Corp lifted its stake in Bristol-Myers Squibb by 649.7% in the second quarter. First Merchants Corp now owns 31,167 shares of the biopharmaceutical company’s stock worth $1,294,000 after purchasing an additional 27,010 shares during the last quarter. Family Firm Inc. purchased a new position in shares of Bristol-Myers Squibb in the second quarter worth about $89,000. Silverleafe Capital Partners LLC purchased a new position in shares of Bristol-Myers Squibb in the second quarter worth about $845,000. Keynote Financial Services LLC boosted its holdings in Bristol-Myers Squibb by 10.6% during the 2nd quarter. Keynote Financial Services LLC now owns 30,705 shares of the biopharmaceutical company’s stock valued at $1,275,000 after acquiring an additional 2,955 shares during the period. Finally, Grove Bank & Trust grew its position in Bristol-Myers Squibb by 14.3% during the 2nd quarter. Grove Bank & Trust now owns 14,903 shares of the biopharmaceutical company’s stock worth $619,000 after acquiring an additional 1,870 shares during the last quarter. Institutional investors own 76.41% of the company’s stock.

Bristol-Myers Squibb Stock Up 1.0 %

Shares of BMY traded up $0.49 on Friday, reaching $48.11. The stock had a trading volume of 8,328,407 shares, compared to its average volume of 15,685,546. The firm has a market capitalization of $97.52 billion, a price-to-earnings ratio of -15.52, a price-to-earnings-growth ratio of 12.51 and a beta of 0.44. The company has a 50-day simple moving average of $44.38 and a 200-day simple moving average of $46.58. Bristol-Myers Squibb has a 12-month low of $39.35 and a 12-month high of $63.41. The company has a debt-to-equity ratio of 2.86, a quick ratio of 0.99 and a current ratio of 1.16.

Bristol-Myers Squibb (NYSE:BMY) last announced its quarterly earnings data on Friday, July 26th. The biopharmaceutical company reported $2.07 EPS for the quarter, beating the consensus estimate of $1.64 by $0.43. The business had revenue of $12.20 billion during the quarter, compared to analyst estimates of $11.54 billion. Bristol-Myers Squibb had a positive return on equity of 12.51% and a negative net margin of 14.06%. The company’s revenue for the quarter was up 8.7% on a year-over-year basis. During the same quarter last year, the firm posted $1.75 earnings per share. Sell-side analysts predict that Bristol-Myers Squibb will post 0.77 EPS for the current year.

Bristol-Myers Squibb Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Thursday, August 1st. Shareholders of record on Friday, July 5th were paid a dividend of $0.60 per share. This represents a $2.40 dividend on an annualized basis and a dividend yield of 4.99%. The ex-dividend date was Friday, July 5th. Bristol-Myers Squibb’s dividend payout ratio is -77.42%.

Analyst Ratings Changes

Several analysts have weighed in on BMY shares. Cantor Fitzgerald reiterated a “neutral” rating and issued a $45.00 price objective on shares of Bristol-Myers Squibb in a research report on Monday, July 22nd. Deutsche Bank Aktiengesellschaft dropped their price target on shares of Bristol-Myers Squibb from $53.00 to $45.00 and set a “hold” rating for the company in a research report on Tuesday, July 23rd. Barclays boosted their price objective on shares of Bristol-Myers Squibb from $41.00 to $42.00 and gave the company an “underweight” rating in a research report on Thursday. StockNews.com upgraded shares of Bristol-Myers Squibb from a “buy” rating to a “strong-buy” rating in a report on Monday, July 29th. Finally, TD Cowen boosted their price target on Bristol-Myers Squibb from $45.00 to $53.00 and gave the company a “hold” rating in a report on Monday, August 12th. Two analysts have rated the stock with a sell rating, twelve have given a hold rating, two have assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat, Bristol-Myers Squibb currently has an average rating of “Hold” and a consensus target price of $54.93.

About Bristol-Myers Squibb

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.